Pacific Biosciences of California (NASDAQ:PACB) Insider Michele Farmer Sells 35,215 Shares

Pacific Biosciences of California, Inc. (NASDAQ:PACB) insider Michele Farmer sold 35,215 shares of the company’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $1.58, for a total transaction of $55,639.70. Following the sale, the insider directly owned 234,044 shares of the company’s stock, valued at $369,789.52. This represents a 13.08% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Michele Farmer also recently made the following trade(s):

• On Wednesday, February 18th, Michele Farmer sold 14,952 shares of Pacific Biosciences of California stock. The shares were sold at an average price of $1.63, for a total transaction of $24,371.76.

Pacific Biosciences of California Price Performance

Shares of NASDAQ:PACB traded up $0.05 during midday trading on Thursday, hitting $1.68. The stock had a trading volume of 4,308,048 shares, compared to its average volume of 7,583,859. The company’s 50-day moving average price is $2.02 and its 200-day moving average price is $1.77. Pacific Biosciences of California, Inc. has a fifty-two week low of $0.85 and a fifty-two week high of $2.73. The company has a quick ratio of 5.40, a current ratio of 6.24 and a debt-to-equity ratio of 17.88. The company has a market capitalization of $507.21 million, a P/E ratio of -0.91 and a beta of 2.27.

Pacific Biosciences of California (NASDAQ:PACB) last announced its quarterly earnings data on Thursday, February 12th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.07. Pacific Biosciences of California had a negative net margin of 341.47% and a negative return on equity of 251.75%. The business had revenue of $44.65 million for the quarter, compared to analysts’ expectations of $44.60 million. As a group, equities research analysts predict that Pacific Biosciences of California, Inc. will post -0.72 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on PACB shares. Piper Sandler raised their price objective on Pacific Biosciences of California from $1.50 to $2.00 and gave the company a “neutral” rating in a research note on Tuesday, November 11th. Weiss Ratings reissued a “sell (e+)” rating on shares of Pacific Biosciences of California in a report on Thursday, January 22nd. Stephens raised their price target on shares of Pacific Biosciences of California from $1.80 to $2.00 and gave the company an “overweight” rating in a research note on Monday, November 10th. Finally, Barclays upped their price objective on shares of Pacific Biosciences of California from $1.50 to $2.00 and gave the stock an “equal weight” rating in a research report on Monday, December 15th. Three investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Pacific Biosciences of California presently has an average rating of “Hold” and an average target price of $2.20.

Institutional Trading of Pacific Biosciences of California

Hedge funds have recently made changes to their positions in the company. ProShare Advisors LLC grew its holdings in shares of Pacific Biosciences of California by 10.2% during the fourth quarter. ProShare Advisors LLC now owns 63,799 shares of the biotechnology company’s stock worth $119,000 after purchasing an additional 5,883 shares during the last quarter. Intech Investment Management LLC boosted its position in Pacific Biosciences of California by 5.2% during the 3rd quarter. Intech Investment Management LLC now owns 132,368 shares of the biotechnology company’s stock worth $169,000 after buying an additional 6,564 shares during the period. Mercer Global Advisors Inc. ADV grew its holdings in Pacific Biosciences of California by 47.9% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 20,663 shares of the biotechnology company’s stock worth $39,000 after acquiring an additional 6,695 shares during the last quarter. Rhumbline Advisers increased its position in Pacific Biosciences of California by 2.1% in the 3rd quarter. Rhumbline Advisers now owns 415,679 shares of the biotechnology company’s stock valued at $532,000 after acquiring an additional 8,532 shares during the period. Finally, Green Alpha Advisors LLC increased its position in Pacific Biosciences of California by 5.4% in the 4th quarter. Green Alpha Advisors LLC now owns 183,466 shares of the biotechnology company’s stock valued at $343,000 after acquiring an additional 9,441 shares during the period.

Pacific Biosciences of California News Summary

Here are the key news stories impacting Pacific Biosciences of California this week:

• Positive Sentiment: Management will participate in a TD Cowen health-care conference fireside chat on March 2, providing a near-term investor event where the company may update guidance, commercialization progress, or product cadence — a potential catalyst if management delivers constructive news. Read More.
• Neutral Sentiment: Despite the sales, insiders retain large holdings after the transactions (final reported post-sale holdings: Michele Farmer ~219k shares; Christian O. Henry ~2.67M shares; Oene Mark Van ~1.74M shares), which may signal liquidity-taking rather than full exits. (See SEC filings below for details.)
• Negative Sentiment: Heavy insider selling reported Feb. 17–18: combined sales by multiple executives totaled roughly 707,731 shares for about $1.13M. Notable filings: Christian O. Henry sold ~472,667 shares across two trades, Michele Farmer sold ~50,167 shares, and Oene Mark Van sold ~184,897 shares — each reducing their stakes by mid-single to low-double-digit percentages. Large, clustered insider sales can raise investor concern about near-term outlook or signal personal diversification, and may pressure sentiment until management commentary clarifies reasons. SEC filings: Christian O. Henry Read More.; Michele Farmer Read More.; Oene Mark Van Read More..

Pacific Biosciences of California Company Profile

Pacific Biosciences of California, Inc develops, manufactures and sells high-performance DNA sequencing systems for genetic and genomic analysis. The company’s proprietary single-molecule, real-time (SMRT) sequencing technology is designed to enable long-read sequencing, offering high accuracy for applications such as de novo genome assembly, transcriptome characterization and structural variation analysis. Pacific Biosciences markets a suite of instruments, including the Sequel and Sequel IIe systems, alongside reagents, consumables and data analysis software to support a range of life science research.

Founded in 2004 and headquartered in Menlo Park, California, Pacific Biosciences has expanded its global reach by serving academic institutions, biotechnology and pharmaceutical companies, and government research centers across North America, Europe and Asia.